Pharmaceutical company Aptalis Holdings files for a $500 million IPO

Comment

Shutterstock photo

Aptalis Holdings, which develops and markets therapies for cystic fibrosis and gastrointestinal disorders, filed on Thursday with the SEC to raise up to $500 million in an initial public offering. The Bridgewater, NJ-based company, which was founded in 1982 and booked $688 million in revenue for the fiscal year ended September 30, 2013, plans to list on the NASDAQ under the symbol APTA. Aptalis Holdings initially filed confidentially on November 4, 2013. Goldman Sachs and J.P. Morgan are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines IPOs
Referenced Stocks: APTA


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com